19 November, 2024: Neuron23 Inc. has announced the Phase 2 NEULARK clinical trial of NEU-411, a brain-penetrant LRRK2 inhibitor, targeting early-stage Parkinson’s disease (PD). The trial employs precision medicine strategies, focusing on individuals with LRRK2-driven PD, who may represent up to 30% of the PD population. This population includes those with familial LRRK2 mutations and…
Category: Parkinson’s Disease
2024 Tom Isaacs Award honours Parkinson’s expert Professor Oliver Bandmann
Cure Parkinson’s and Van Andel Institute (VAI) have announced Professor Oliver Bandmann as the winner of the 2024 Tom Isaacs Award, which honours researchers who closely collaborate with the Parkinson’s community. The award was virtually presented to Professor Bandmann as part of the annual Grand Challenges in Parkinson’s Disease symposium and parallel Rallying to the…
Parkinson’s disease therapy Vyalev gets FDA approval
AbbVie announced on 17th October that the US Food and Drug Administration (FDA) has approved VYALEV™ (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD). The treatment is approved in 35 countries. The approval was supported by…
Ophthalmic acid – its role in motor function control
Brain molecule reverses movement deficits of Parkinson’s, offering new therapeutic target October 4th 2024: A research team from the University of California, Irvine is the first to reveal that a molecule in the brain – ophthalmic acid – unexpectedly acts like a neurotransmitter similar to dopamine in regulating motor function, offering a new therapeutic target…
Cannabis-based medicine for neurodegenerative diseases
Avextra announces the approval of NEUROBIS by the Italian Medicines Agency: A Phase II clinical trial Avextra AG, a European manufacturer and developer of Cannabis-based medicines located in Germany, has announced that both the Italian Medicines Agency AIFA and the Italian Ministry of Health have granted formal approval for a multi-centre Phase II study to…
US launch of CREXONT® for Parkinson’s disease
23 September 2024: Amneal Pharmaceuticals has announced that it has launched CREXONT® (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease. CREXONT® is a novel, oral formulation of carbidopa/levodopa (CD/LD) that combines both immediate-release granules and extended-release pellets. “We are pleased to launch CREXONT and make it broadly available to healthcare providers and patients. The…
Phase 1 study of UB-312 shows promise in Parkinson’s disease
In a study published in Nature Medicine on 18th September 2024, Parkinson’s patients reported improved daily movement with Vaxxinity’s Parkinson’s drug UB-312. The small trial, which included work from researchers at the University of Texas, the Mayo Clinic, and the Michael J. Fox Foundation for Parkinson’s Research, included only 20 people with Parkinson’s. However, it…
CREXONT for Parkinson’s disease – Amneal’s capsules gain FDA approval
August 8th 2024: The US Food and Drug Administration (FDA) has granted approval to Amneal Pharmaceuticals‘ CREXONT (carbidopa/levodopa) extended-release capsules for the treatment of Parkinson’s disease. This novel oral formulation combines immediate-release granules and extended-release pellets, meaning that therapeutic levels of levodopa and carbidopa may be maintained with less frequent dosing to maximise “good on” time,…
CE Mark for Image Guided Programming Software for Deep Brain Stimulation
Boston’s Vercise™ Neural Navigator 5 with STIMVIEW™ XT technology is designed to streamline procedure for people living with neurological conditions Boston Scientific Corporation has obtained a CE Mark on the Vercise™ Neural Navigator 5 Software with STIMVIEW™ XT technology, which when used as part of the Vercise Genus™ Deep Brain Stimulation (DBS) Systems, can provide…
